Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials

Gentleman R: R: A language for data analysis and graphics

Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,747 · see citing works

R: A Language for Data Analysis and Graphics

Ihaka, R., & Gentleman, R. C. (1996) · Journal of Computational and Graphical Statistics · doi:10.2307/1390807 · Cited by 4,245 · see citing works

Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment

Martín, M. A., Westfall, P. H., & Young, S. (1993) · Biometrics · doi:10.2307/2533464 · Cited by 2,308 · see citing works

Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus

Lechner, F., Wong, D., Dunbar, P. R., Chapman, R. W., Chung, R. T., Dohrenwend, P. B., Robbins, G. K., Phillips, R., Klenerman, P., & Walker, B. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.9.1499 · Cited by 1,269 · see citing works

Multiple Hypothesis Testing in Microarray Experiments

Dudoit, S., Shaffer, J. P., & Boldrick, J. C. (2003) · Statistical Science · doi:10.1214/ss/1056397487 · Cited by 1,054 · see citing works

Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment

Chaubey, Y. P., Westfall, P. H., & Young, S. S. (1993) · Technometrics · doi:10.2307/1270279 · Cited by 943 · see citing works

Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytes choriomeningitis

Zinkernagel, R. M., & Doherty, P. C. (1974) · Nature · doi:10.1038/251547a0 · Cited by 854 · see citing works

Encyclopedia of biostatistics

(1999) · Choice Reviews Online · doi:10.5860/choice.36-3094 · Cited by 569 · see citing works

Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells

Czerkinsky, C. C., Andersson, G., Ekre, H.-P. T., Nilsson, L., Klareskog, L., & Ouchterlony, Ö. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90079-8 · Cited by 495 · see citing works

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.

Rowland‐Jones, S., Dong, T., Fowke, K. R., Kimani, J., Krausa, P., Newell, H., Blanchard, T., Ariyoshi, K., Oyugi, J. O., NGUGI, E. N., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4314 · Cited by 419 · see citing works

Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma.

Olsson, T. P., Zhi, W. W., Höjeberg, B., Kostulas, V., Jiang, Y., Anderson, G., Ekre, H. P., & Link, H. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114800 · Cited by 370 · see citing works

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

Currier, J. R., Kuta, E. G., Turk, E., Earhart, L. B., Loomis-Price, L. D., Janetzki, S., Ferrari, G., Birx, D. L., & Cox, J. H. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00535-x · Cited by 320 · see citing works

CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained

Lechner, F., Gruener, N. H., Urbani, S., Uggeri, J., Santantonio, T. A., Kammer, A. R., Cerny, A., Phillips, R., Ferrari, C. I., Pape, G. R., et al. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200009)30:9 · Cited by 311 · see citing works

Enhanced: The Need for a Global HIV Vaccine Enterprise

Klausner, R. D., Fauci, A. S., Corey, L., Nabel, G. J., Gayle, H. D., Berkley, S., Haynes, B. F., Baltimore, D., Collins, C., Douglas, R. G., et al. (2003) · Science · doi:10.1126/science.1086916 · Cited by 197 · see citing works

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen

Rahman, F., Dahmen, A., Herzog‐Hauff, S., Böcher, W. O., Galle, P. R., & Löhr, H. F. (2000) · Hepatology · doi:10.1002/hep.510310237 · Cited by 153 · see citing works

Immunologic Control of HIV-1

Gandhi, R. T., & Walker, B. D. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104011 · Cited by 145 · see citing works

Characterization of the expression pattern of p63α and δnp63α in benign and malignant oral epithelial lesions

Nylander, K., Coates, P. J., & Hall, P. A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000801)87:3 · Cited by 142 · see citing works

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

Nagorsen, D., Keilholz, U., Rivoltini, L., Schmittel, A. H., Letsch, A., Asemissen, A. M., Berger, G., Buhr, H. J., Thiel, E., & Scheibenbogen, C. (2000) · PubMed · Cited by 137 · see citing works

Moving to Human Immunodeficiency Virus Type 1 Vaccine Efficacy Trials: Defining T Cell Responses As Potential Correlates of Immunity

Russell, N. D., Hudgens, M. G., Ha, R., Havenar‐Daughton, C., & McElrath, M. J. (2003) · The Journal of Infectious Diseases · doi:10.1086/367702 · Cited by 118 · see citing works

Quantification of Self-Recognition in Multiple Sclerosis by Single-Cell Analysis of Cytokine Production

Pelfrey, C. M., Rudick, R. A., Cotleur, A. C., Lee, J.-C., Tary‐Lehmann, M., & Lehmann, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1641 · Cited by 116 · see citing works

Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children

Goulder, P., Brander, C., Annamalai, K., Mngqundaniso, N., Govender, U., Tang, Y., He, S., Hartman, K. E., O’Callaghan, C. A., Ogg, G. S., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.12.5679-5690.2000 · Cited by 114 · see citing works

Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.

Link, H., Olsson, O., Sun, J., Wang, W. Z., Andersson, G., Ekre, H. P., Brenner, T., Abramsky, O., & Olsson, T. P. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115253 · Cited by 113 · see citing works

Parallel regulation of IL-4 and IL-5 in human helminth infections

Mahanty, S., Abrams, J. S., King, C. L., Limaye, A. P., & Nutman, T. B. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3567 · Cited by 106 · see citing works

Identification of Dominant Optimal HLA-B60- and HLA-B61-Restricted Cytotoxic T-Lymphocyte (CTL) Epitopes: Rapid Characterization of CTL Responses by Enzyme-Linked Immunospot Assay

Altfeld, M. A., Piechocka‐Trocha, A., Eldridge, R. L., Rosenberg, E. S., Phillips, M. N., Addo, M. M., Sékaly, R., Kalams, S. A., Burchett, S. K., McIntosh, K., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8541-8549.2000 · Cited by 98 · see citing works

Number of interleukin‐4‐ and interferon‐γ‐secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation

ElGhazali, G. E., Paulie, S., Andersson, G., Hansson, Y., Holmquist, G., Sun, J., Olsson, T. P., Ekre, H. P., & Troye‐Blomberg, M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231103 · Cited by 96 · see citing works

Multiple Comparisons by Rerandomization Tests

Petrondas, D. A., & Gabriel, K. R. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10477045 · Cited by 64 · see citing works

Monitoring of cellular responses after vaccination against tetanus toxoid: Comparison of the measurement of IFN-γ production by ELISA, ELISPOT, flow cytometry and real-time PCR

Joel, T., Burny, W., Dahmani, S., Zhou, L., Stordeur, P., Byl, B., & Groote, D. D. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.07.014 · Cited by 62 · see citing works

Quantification of CD8+T Lymphocytes Responsive to Human Immunodeficiency Virus (HIV) Peptide Antigens in HIV‐Infected Patients and Seronegative Persons at High Risk for Recent HIV Exposure

Herr, W., Protzer, U., Lohse, A. W., Gerken, G., Büschenfelde, K. M. Z., & Wölfel, T. (1998) · The Journal of Infectious Diseases · doi:10.1086/517449 · Cited by 52 · see citing works

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials

Hudgens, M. G., Self, S. G., Chiu, Y.-L., Russell, N. D., Horton, H., & McElrath, M. J. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.01.018 · Cited by 42 · see citing works

HIV-1–Specific CD4 Helper Function in Persons With Chronic HIV-1 Infection on Antiviral Drug Therapy as Measured by ELISPOT After Treatment With an Inactivated, gp120-Depleted HIV-1 in Incomplete Freund's Adjuvant

Moss, R. B., Webb, E., Giermakowska, W., Jensen, F. C., Savary, J. R., Wallace, M. R., & Carlo, D. J. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200007010-00012 · Cited by 33 · see citing works

Multiple Comparisons by Rerandomization Tests

Petrondas, D. A., & Gabriel, K. R. (1983) · Journal of the American Statistical Association · doi:10.2307/2288209 · Cited by 26 · see citing works

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants

Slyker, J. A., Lohman, B. L., Mbori‐Ngacha, D., Reilly, M., Wee, E. G., Dong, T., McMichael, A. J., Rowland‐Jones, S., Hanke, T., & John-Stewart, G. C. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.145 · Cited by 22 · see citing works

Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects

Eyeson, J., King, D. F. L., Boaz, M. J., Sefia, E., Tomkins, S., Waters, A., Easterbrook, P., & Vyakarnam, A. (2003) · AIDS · doi:10.1097/00002030-200311070-00004 · Cited by 16 · see citing works

Statistical evaluation of HIV vaccines in early clinical trials

Moodie, Z., Rossini, A. J., Hudgens, M. G., Gilbert, P. B., Self, S. G., & Russell, N. D. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2005.11.008 · Cited by 15 · see citing works

Use of Interferon-γ ELISPOT in Monitoring Immune Responses in Humans

Matijevic, M., & Urban, R. G. (2005) · Humana Press eBooks · doi:10.1385/1-59259-903-6:237 · Cited by 6 · see citing works

Untitled work

(2000) · doi:10.1002/1097-0215(20001015)88:2

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · see citing works

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432 · see citing works

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 845 · see citing works

Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector

Catanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509258 · Cited by 319 · see citing works

Response definition criteria for ELISPOT assays revisited

Moodie, Z., Price, L. S., Gouttefangeas, C., Mander, A., Janetzki, S., Löwer, M., Welters, M. J. P., Ottensmeier, C. H. H., van der Burg, S. H., & Britten, C. M. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0875-4 · Cited by 225 · see citing works

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

Catanzaro, A. T., Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.050 · Cited by 151 · see citing works

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

Koup, R. A., Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M., Larkin, B. D., Enama, M. E., Ledgerwood, J. E., Bailer, R. T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009015 · Cited by 133 · see citing works

Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer

Disis, M. L., Guthrie, K. A., Liu, Y., Coveler, A. L., Higgins, D. M., Childs, J. S., Dang, Y., & Salazar, L. G. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5143 · Cited by 100 · see citing works

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial

Graham, B. S., Enama, M. E., Nason, M., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., Plummer, S. A., Mascola, J. R., Bailer, R. T., Roederer, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059340 · Cited by 85 · see citing works

Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C gag Vaccine in Healthy HIV-1-Uninfected Adults

Wecker, M. T., Gilbert, P. B., Russell, N. D., Hural, J., Allen, M., Pensiero, M. N., Chulay, J. D., Chiu, Y.-L., Karim, S. S. A., & Burke, D. S. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00258-12 · Cited by 70 · see citing works

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

Spearman, P. W., Kalams, S. A., Elizaga, M. L., Metch, B. J., Chiu, Y.-L., Allen, M., Weinhold, K. J., Ferrari, G., Parker, S., McElrath, M. J., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.051 · Cited by 62 · see citing works

A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers

Ramanathan, V. D., Kumar, M., Mahalingam, J., Pattabiraman, S., Narayanan, P. R., Solomon, S., Panicali, D., Chakrabarty, S., Cox, J. H., Sayeed, E., et al. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2009.0096 · Cited by 58 · see citing works

A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients

Gasser, O., SHARPLES, K. J., Barrow, C., Williams, G. M., Bauer, E., Wood, C. E., Mester, B., Dzhelali, M., Caygill, G., Jones, J., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2085-9 · Cited by 58 · see citing works

Response Determination Criteria for ELISPOT: Toward a Standard that Can Be Applied Across Laboratories

Moodie, Z., Price, L. S., Janetzki, S., & Britten, C. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-325-7_15 · Cited by 52 · see citing works

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC

Şahin, U., Schmidt, M., Derhovanessian, E., Cortini, A., Vogler, I., Omokoko, T., Godehardt, E., Attig, S., Newrzela, S., GRUTZNER, J., et al. (2026) · Nature · doi:10.1038/s41586-025-10004-2 · Cited by 50 · see citing works

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials

Fiore-Gartland, A. J., Manso, B. A., Friedrich, D. P., Gabriel, E. E., Finak, G., Moodie, Z., Hertz, T., Rosa, S. C. D., Frahm, N., Gilbert, P. B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147812 · Cited by 48 · see citing works

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories

Gill, D. K., Huang, Y., Levine, G. L., Sambor, A., Carter, D. K., Sato, A., Kopycinski, J. T., Hayes, P., Hahn, B., Birungi, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014330 · Cited by 44 · see citing works

Host Genetic Determinants of T Cell Responses to the MRKAd5 HIV-1 gag/pol/nef Vaccine in the Step Trial

Fellay, J., Frahm, N., Shianna, K. V., Cirulli, E. T., Casimiro, D. R., Robertson, M. N., Haynes, B. F., Geraghty, D. E., McElrath, M. J., & Goldstein, D. B. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq125 · Cited by 43 · see citing works

Epitope specific T‐cell responses against influenza A in a healthy population

Savić, M., Dembinski, J. L., Kim, Y., Tunheim, G., Cox, R. J., Oftung, F., Peters, B., & Mjaaland, S. (2015) · Immunology · doi:10.1111/imm.12548 · Cited by 42 · see citing works

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial

Koblin, B. A., Casapía, M., Morgan, C. A., Li, Q., Wang, Z. M., Defawe, O., Baden, L. R., Goepfert, P., Tomaras, G. D., Montefiori, D. C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024517 · Cited by 42 · see citing works

Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses

Quandt, J., Schlude, C., Bartoschek, M., Will, R. D., Cid-Arregui, Á., Schölch, S., Reißfelder, C., Weitz, J., Schneider, M. A., Wiemann, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500671 · Cited by 42 · see citing works

Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials

Jin, X., Morgan, C. A., Yu, X., Rosa, S. C. D., Tomaras, G. D., Montefiori, D. C., Kublin, J. G., Corey, L., & Keefer, M. C. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.036 · Cited by 38 · see citing works

Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method

Patton, K. S., Harrison, M. T., Long, B. R., Lau, K., Holcomb, J., Owen, R. E., Kasprzyk, T., Janetzki, S., Zoog, S. J., & Vettermann, C. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.012 · Cited by 37 · see citing works

Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tract

Posavad, C. M., Zhao, L., Mueller, D. E., Stevens, C. E., Huang, M. L., Wald, A., & Corey, L. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.47 · Cited by 34 · see citing works

Peptide Impurities in Commercial Synthetic Peptides and Their Implications for Vaccine Trial Assessment

Currier, J. R., Galley, L. M., Wenschuh, H., Morafo, V., Ratto‐Kim, S., Gray, C. M., Maboko, L., Höelscher, M., Marovich, M., & Cox, J. H. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00284-07 · Cited by 33 · see citing works

Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis

Santos, R. G., Buying, A., Sabri, N., Yu, J. S., Gringeri, A. J., BENDER, J. G., Janetzki, S., Pinilla, C., & Judkowski, V. A. (2014) · Cells · doi:10.3390/cells4010001 · Cited by 32 · see citing works

Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120

Cleghorn, F. R., Pape, J. W., Schechter, M., Bartholomew, C., Sanchez, J., Jack, N., Metch, B. J., Hansen, M., Allen, M., Cao, H., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318149297d · Cited by 31 · see citing works

Normal Distribution of CD8+ T-Cell-Derived ELISPOT Counts within Replicates Justifies the Reliance on Parametric Statistics for Identifying Positive Responses

Karulin, A. Y., Caspell, R., Dittrich, M. T., & Lehmann, P. (2015) · Cells · doi:10.3390/cells4010096 · Cited by 27 · see citing works

Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy

Xu, W., Pang, C., Song, C., Qian, J., Feola, S., Cerullo, V., Li, F., Yu, H., & Lehto, V. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.073 · Cited by 25 · see citing works

Statistical Analysis of ELISPOT Assays

Dittrich, M. T., & Lehmann, P. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-325-7_14 · Cited by 25 · see citing works

Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects

Baden, L. R., Blattner, W. A., Morgan, C. A., Huang, Y., Defawe, O., Sobieszczyk, M. E., Kochar, N. K., Tomaras, G. D., McElrath, M. J., Russell, N. D., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir615 · Cited by 25 · see citing works

Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners

Pala, P., Serwanga, J., Watera, C., Ritchie, A. J., Moodie, Z., Wang, M., Goonetilleke, N. P., Birabwa, E., Hughes, P. J., Senkaali, D., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00721-13 · Cited by 20 · see citing works

Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry

Rountree, W., Vandergrift, N., Bainbridge, J., Sanchez, A. M., & Denny, T. N. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.01.007 · Cited by 19 · see citing works

Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer

Carluccio, S., Delbue, S., Signorini, L., Setola, E., Bagliani, A., Valle, A. D., Galli, A., Ferrante, P., & Bregni, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24886 · Cited by 16 · see citing works

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027)

Kaleebu, P., Njai, H. F., Wang, L., Jones, N. G., Ssewanyana, I., Richardson, P., Kintu, K., Emel, L., Musoke, P., Fowler, M. G., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000435600.65845.31 · Cited by 16 · see citing works

A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer

Disis, M. L., Dang, Y., Coveler, A. L., Childs, J. S., Higgins, D. M., Liu, Y., Zhou, J., Mackay, S., & Salazar, L. G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3578 · Cited by 14 · see citing works

The High Frequency of HIV Type 1-Specific Cellular Immune Responses in Seronegative Individuals with Parenteral and/or Heterosexual HIV Type 1 Exposure

Murashev, B., Nazarenko, O. V., Akulova, E. B., Artemyeva, A. K., Verevochkin, S. V., Шаболтас, А. В., Skochilov, R. V., Toussova, O., & Kozlov, A. P. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0335 · Cited by 14 · see citing works

Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2

Posavad, C. M., Magaret, A., Zhao, L., Mueller, D. E., Wald, A., & Corey, L. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.028 · Cited by 13 · see citing works

Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials

Gilbert, P. B., Yu, X., & Rotnitzky, A. G. (2013) · Statistics in Medicine · doi:10.1002/sim.6006 · Cited by 13 · see citing works

Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Frey, S. E., Peiperl, L., McElrath, M. J., Kalams, S. A., Goepfert, P., Keefer, M. C., Baden, L. R., Lally, M., Mayer, K. H., Blattner, W. A., et al. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00450-14 · Cited by 12 · see citing works

VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens

Carri, I., Schwab, E., Triviño, J. C., von Euw, E. M., Nielsen, M., Mordoh, J., & Barrio, M. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1496204 · Cited by 11 · see citing works

Recent developments in clinical trial designs for HIV vaccine research

Richert, L. E., Lhomme, É., Fagard, C., Lévy, Y., Chêne, G., & Thiébaut, R. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011974 · Cited by 11 · see citing works

Sources of diversity in T cell epitope discovery

Chang, C. X. L. (2011) · Frontiers in bioscience · doi:10.2741/3895 · Cited by 11 · see citing works

Theoretical and practical considerations for validating antigen-specific B cell ImmunoSpot assays

Lehmann, P., Karulin, A. Y., Becza, N., Yao, L., Liu, Z., Chepke, J., Maul‐Pavicic, A., Wolf, C., Köppert, S., Valente, A. V., et al. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113817 · Cited by 10 · see citing works

Defining ELISpot cut-offs from unreplicated test and control wells

Alexander, N. D. E., Fox, A., Lien, V. T. K., Dong, T., Lee, L. Y.-H., Hằng, N. L. K., Mai, L. Q., & Horby, P. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.02.014 · Cited by 10 · see citing works

Use of ESAT-6-CFP-10 fusion protein in the bovine interferon-gamma ELISPOT assay for diagnosis of Mycobacterium bovis infection in cattle

Sugumar, P., Veerasami, M., Appana, G., Chandran, D., Das, D., & Srinivasan, V. A. (2012) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2012.06.001 · Cited by 9 · see citing works

Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies

Rountree, W., Berrong, M., Sanchez, A. M., Denny, T. N., & Ferrari, G. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.03.004 · Cited by 8 · see citing works

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial

Sarwar, U. N., Novik, L., Enama, M. E., Plummer, S. A., Koup, R. A., Nason, M., Bailer, R. T., McDermott, A. B., Roederer, M., Mascola, J. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106240 · Cited by 5 · see citing works

2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A – Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B – Regulatory Agencies’ Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))

Hersey, S., McGuire, K., Kholmanskikh, O., Bivi, N., Bandukwala, A., Gong, B., Irwin, C. R., Ray, S., Gunsior, M., Avanesov, A. S., et al. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2599698 · Cited by 4 · see citing works

The immunologic dominance of an epitope within a rationally designed poly-epitope vaccine is influenced by multiple factors

Shu, J., Shen, W. H., Liu, H., Zhou, Y., Li, J., Zhuang, Y., Huang, Z., Yin, S., Jiang, L., Sun, Y., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.02.069 · Cited by 4 · see citing works

Study of the BCG Vaccine-Induced Cellular Immune Response in Schoolchildren in Antananarivo, Madagascar

Ranaivomanana, P. P., Raharimanga, V., Dubois, P. M., Richard, V., & Razanamparany, V. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127590 · Cited by 4 · see citing works

Is the current use of ‘positivity’ thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?

Richert, L. E., & Thiébaut, R. (2013) · AIDS · doi:10.1097/qad.0b013e328360d52e · Cited by 3 · see citing works

Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses

Dintwe, O., Rosa, S. C. D., Huang, Y., Flach, B., Manso, B. A., Carter, D., Omar, F. L., Schwedhelm, K. V., Yu, C., Lu, H., et al. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ma0522-668r · Cited by 3 · see citing works

Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates.

Wu, J., Chen, G., Zhuang, F.-C., Gao, M. Q., Wu, C.-D., Zhan-long, H., Jiang, Y., Li, J.-B., Bao, J.-Y., & Mao, Z. (2018) · Europe PMC (PubMed Central) · Cited by 3 · see citing works

A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data

Ström, P., Støer, N. C., Borthwick, N., Dong, T., Hanke, T., & Reilly, M. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.05.006 · Cited by 2 · see citing works

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial

Sellars, M., Frank, J. A., Shim, B., Vanasse, A. P., Liu, R., Forman, C., Tu, C. R., Tabata, K. K., Kowelewski, A., Cheng, S.-C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04717-8 · Cited by 1 · see citing works

A New Statistical Method for Analyzing Elispot Data

Huang, S. (2017) · Biometrics & Biostatistics International Journal · doi:10.15406/bbij.2017.05.00131 · Cited by 1 · see citing works

Statistical Estimation & Inference of Cell Counts from ELISPOT Limiting Dilution Assays

Yang, H., Topham, D. J., Holden‐Wiltse, J., & Wu, H. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.790645 · Cited by 1 · see citing works

Recognition of Core‐ and Polymerase‐derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients

Huang, D., Sansas, B., Jiang, J., Gong, Q., Jin, G.-D., Calais, V., Yu, D., Zhu, M. Y., Wei, D., Zhang, D. H., et al. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12791 · Cited by 1 · see citing works

Reduced Virus Load in Lungs of Pigs Challenged with Porcine Reproductive and Respiratory Syndrome Virus after Vaccination with Virus Replicon Particles Encoding Conserved PRRSV Cytotoxic T-Cell Epitopes

Welner, S., Ruggli, N., Liniger, M., Summerfield, A., Larsen, L. E., & Jungersen, G. (2021) · Vaccines · doi:10.3390/vaccines9030208 · Cited by 1 · see citing works

Theoretical and practical considerations for validating antigen-specific B cell ImmunoSpot assaysPreprint

Lehmann, P., Karulin, A. Y., Becza, N., Yao, L., Liu, Z., Chepke, J., Maul‐Pavicic, A., Wolf, C., Köppert, S., Valente, A. V., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3994852/v1 · Cited by 1 · see citing works

Estimating individual peptide effects from grouped Elispot data

Ström, P. (2013)

GENERATION OF TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FROM PERIPHERAL BLOOD OF COLORECTAL CANCER PATIENTS FOR ADOPTIVE T-CELL TRANSFER

Molecolare, M. (2013)

Data Analysis

Janetzki, S. (2016) · Techniques in life science and biomedicine for the non-expert · doi:10.1007/978-3-319-45295-1_7

Theoretical and Practical Considerations for Validating Antigen-Specific B Cell Immunospot AssaysPreprint

Lehmann, P., Karulin, A. Y., Becza, N., Yao, L., Liu, Z., Chepke, J., Maul‐Pavicic, A., Wolf, C., Köppert, S., Valente, A. V., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4776655

T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children

Vogler, I., Renken, S., Hilker, R., Lui, B. G., Finlayson, A., Gurtman, A., Sabharwal, C., Kitchin, N. R. E., Lockhart, S. P., Gruber, W. C., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf699

Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

Gomez, S., DiCioccio, R. A., Geiger, A. E., Grant, M., Reynolds, E., Datar, A. A., McCann, C. D., Tanna, J., Kukadiya, D., Hoq, F., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04449-9

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials

Hudgens, M. G., Self, S. G., Chiu, Y.-L., Russell, N. D., Horton, H., & McElrath, M. J. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.01.018 · Cited by 42 · see citing works

Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay

Dubey, S. A., Clair, J. S., Fu, T., Guan, L., Long, R. S., Mogg, R., Anderson, K., Collins, K., Gaunt, C., Fernandez, V. R., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3180377b5b · Cited by 95 · see citing works

Design and Validation of an Enzyme-Linked Immunospot Assay for Use in Clinical Trials of Candidate HIV Vaccines

Mwau, M., McMichael, A. J., & Hanke, T. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760019301 · Cited by 73 · see citing works

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

Currier, J. R., Kuta, E. G., Turk, E., Earhart, L. B., Loomis-Price, L. D., Janetzki, S., Ferrari, G., Birx, D. L., & Cox, J. H. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00535-x · Cited by 320 · see citing works

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories

Gill, D. K., Huang, Y., Levine, G. L., Sambor, A., Carter, D. K., Sato, A., Kopycinski, J. T., Hayes, P., Hahn, B., Birungi, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014330 · Cited by 44 · see citing works